Cargando…

Corrigendum to ‘How I treat medullary thyroid cancer’: [ESMO Open Volume 6, Issue 3, June 2021, 100183]

Detalles Bibliográficos
Autores principales:	Kiesewetter, B., Riss, P., Scheuba, C., Raderer, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184552/ https://www.ncbi.nlm.nih.gov/pubmed/35688063 http://dx.doi.org/10.1016/j.esmoop.2022.100516

Ejemplares similares

Corrigendum to ‘Remembering Professor José Baselga’: [ESMO Open Volume 6, Issue 3, June 2021, 100121]
por: Tabernero, J.
Publicado: (2021)

How I treat medullary thyroid cancer
por: Kiesewetter, B., et al.
Publicado: (2021)

Corrigendum to ‘COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)’ [ESMO Open Volume 6, Issue 3, June 2021, 100165]
por: Bianchi, F., et al.
Publicado: (2021)

Corrigendum to ‘Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review’: [ESMO Open Volume 6, Issue 5, October 2021, 100276]
por: Garutti, M., et al.
Publicado: (2021)

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
por: Banna, G.L., et al.
Publicado: (2021)

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273]
por: Reck, M., et al.
Publicado: (2021)

Corrigendum to ‘Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients’: [ESMO Open Volume 6, Issue 2, April 2021, 100081]
por: Richter, R., et al.
Publicado: (2021)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
por: De Angelis, C., et al.
Publicado: (2021)

Corrigendum to ‘Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study’: [ESMO Open Volume 7, Issue 2, April 2022, 100466]
por: Sinn, K., et al.
Publicado: (2022)

Corrigendum to “How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain”: [ESMO Open, 7 (2022) 100462]
por: Castañeda, A., et al.
Publicado: (2022)

Corrigendum to “How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer”
por: Prazeres, Hugo, et al.
Publicado: (2016)

Management of adrenocortical carcinoma: are we making progress?
por: Kiesewetter, Barbara, et al.
Publicado: (2021)

Asymptomatic renal pseudoaneurysm after percutaneous renal biopsy [Volume 32, Issue 2, June 2013, pp. 87–89]
por: Young Yun, Gi, et al.
Publicado: (2013)

Corrigendum to “Innovative human resource management strategies during the COVID-19 pandemic: A systematic narrative review approach” [Heliyon 7 (6) (June 2021) e07233]
por: Azizi, Mohammad Reza, et al.
Publicado: (2022)

Corrigendum to “New Issues in the Management of Osteoporosis”
por: Sirola, Joonas, et al.
Publicado: (2017)

Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy?
por: Brammen, Lindsay, et al.
Publicado: (2018)

Corrigendum to “Central venous disease in hemodialysis patients” [Volume 38, Issue 3, September 2019, Pages 309-317]
por: Park, Hoon Suk, et al.
Publicado: (2020)

From ESMO TAT 2021
por: Killock, David
Publicado: (2021)

From the ESMO Congress 2021
por: Sidaway, Peter
Publicado: (2021)

Corrigendum to “Implementing patient direct access to musculoskeletal physiotherapy in primary care: views of patients, general practitioners, physiotherapists and clinical commissioners in England” [Physiotherapy 111 (June) (2021) 31–39]
por: Igwesi-Chidobe, Chinonso N., et al.
Publicado: (2021)

Corrigendum to: CHEST 2021;160(1):175-186
Publicado: (2023)

Corrigendum to “Assesment of SARS-CoV-2 infection-in dentists and supporting staff at a university dental hospital in Argentina”. Journal of Oral Biology and Craniofacial Research Volume 11, Issue 2 (2021) Pages 169–173
por: Puia, Sebastian, et al.
Publicado: (2021)

ESMO 2017—my personal highlights
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

The Blood Biomarkers of Thyroid Cancer [Corrigendum]
Publicado: (2022)

Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152]
por: Koga, Satoko, et al.
Publicado: (2022)

Corrigendum to ‘A More Fitting Approach to Mask Policy’ The American Journal of Medicine, Volume 135, Issue 11 (2022) 1280-1281
por: Levine, Marc
Publicado: (2023)

Corrigendum to “Multiple group membership, social network size, allostatic load and well-being: A mediation analysis” [Volume 151 (December 2021) 110636]
por: Gallagher, Stephen, et al.
Publicado: (2022)

Corrigendum to: Ethical and policy issues raised by uterus transplants
por: O’Donovan, Laura, et al.
Publicado: (2020)

Corrigendum to “Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015” [Volume 6, Issue 4, August 2015, 269–278]
Publicado: (2016)

Corrigendum to “Self-isolation” [J. Math. Econom. 93 (2021) 102483]
por: Baril-Tremblay, Dominique, et al.
Publicado: (2022)

ESMO 2021—highlights in colorectal cancer
por: Weiss, Lukas
Publicado: (2022)

Corrigendum to ``Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats'' [Current Therapeutic Research Volume 95, 2021, 100647]
por: Shalaby, Mohammed Fouad, et al.
Publicado: (2022)

Patient Selection for Bronchoscopic Lung Volume Reduction [Corrigendum]
Publicado: (2020)

Corrigendum: Estimation of C. elegans cell- and tissue volumes
Publicado: (2022)

Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
por: Pandit, Anuja, et al.
Publicado: (2021)

Corrigendum to “Challenges in Interpretation of Thyroid Function Tests in Pregnant Women with Autoimmune Thyroid Disease”
por: Feldt-Rasmussen, Ulla, et al.
Publicado: (2017)

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’: [ESMO Open Volume 6, Issue 3, June 2021, 100101]
por: Choueiri, T.K., et al.
Publicado: (2021)

My burning issues in neuroendocrine tumours (NET)
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

Corrigendum to “Exposure to Dichlorodiphenyltrichloroethane and the Risk of Breast Cancer: A Systematic Review and Meta-analysis [Volume 5, Issue 2, April 2014, Pages 77–84]”
por: Park, Jae-Hong, et al.
Publicado: (2015)

Corrigendum to: The Role of Iodine for Thyroid Function in Lactating Women and Infants
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6q0deigkffnmmog7qhcj6ql7ik